Drugs / Marizomib
Marizomib
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04341311 | Aug 2020 → Feb 2024 | diffuse intrinsic pontine glioma | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT02903069 | Aug 2016 → Jan 2021 | glioblastoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02103335 | Jun 2014 → Oct 2016 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00667082 | Mar 2008 → Jan 2010 | malignant pancreatic neoplasm, melanoma, non-small cell lung carcinoma, plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00629473 | Jul 2007 → Apr 2013 | cancer of unknown primary site | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00396864 | May 2006 → Mar 2010 | cancer, lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05050305 | Mar 2024 → Dec 2025 | plasma cell myeloma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT03727841 | Jan 2020 → Apr 2021 | anaplastic ependymoma, ependymoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT03463265 | Aug 2018 → Aug 2022 | glioblastoma | Aadi Bioscience, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03345095 | Jul 2018 → Aug 2022 | glioblastoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT04644107 Background | — | neoplasm | Celgene Corporation | No longer available | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | marizomib | “an investigational drug known as marizomib (MRZ) will improve the treatment of newly diagnosed glioblastoma patients” NCT02903069 ↗ |
| Known as | marizomib (MRZ) | “marizomib (MRZ)” NCT03463265 ↗ |
| Known as | MRZ | “an investigational drug known as marizomib (MRZ) will improve the treatment of newly diagnosed glioblastoma patients” NCT02903069 ↗1“Arm A, Cohort 5: nab-sirolimus + marizomib (MRZ) in patients with recurrent high grade glioma” NCT03463265 ↗ |
| Known as | NPI-0052 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00396864 ↗ |
| Known as | Salinosporamide a | ChEMBL registry synonym — accepted as the source's own label CHEMBL371405 ↗ |
| Action | Inhibit | “NPI-0052 inhibits the chymotrypsin-like (CT-L), caspase-like (C-L), and trypsin-like (T-L) activity of human erythrocyte-derived 20S proteasomes.” NCT00396864 ↗ |
| Modality | Small molecule | — CHEMBL371405 ↗ |
| Route | Intravenous | “NPI-0052 IV injection” NCT00396864 ↗ |